151
|
Machtay M, Swann S, Komaki R, Byhardt R, Paulus R, Sause W, Curran W, Albain K, Movas B. O-041 What is the meaning of local-regional control after chemoradiation for locally advanced NSCLC? An RTOG analysis. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80173-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
152
|
Komaki R, Allen P, Roth J, Swisher S, Rice D, Fossella F, Herbst R, Oh Y, Munden R, Cox J. PD-044 Optimal treatment for superior sulcus tumors (SST): Surgery first followed by adjunct RT/ChT improved survival for patients with resectable SST. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80377-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
153
|
Yom S, Liao Z, Liu H, Allen P, Chang J, Jeter M, Guerrero T, Stevens C, Cox J, Komaki R. O-152 Analysis of acute toxicity results of intensity modulated radiationtherapy (IMRT) in the treatment of non-small cell lung cancer (NSCLC). Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80286-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
154
|
Liao Z, Komaki R, Milas L, Chen Y, Kies M, Chang J, Jeter M, Guerrero T, Blumenschein G, Cox J. P-959 A dose escalation clinical trial using thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer (NSCLC). Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)81452-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
155
|
Komaki R, Swann S, Byhardt R, Cox J, Scott C, Sause W. PD-074 Does response rate in the induction chemotherapy predictsurvival for locally advanced non-small cell lung cancer (LANSCLC)?: Secondary analysis of RTOG 8804/8808. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80407-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
156
|
Chang J, Dong L, Mohan R, Liao Z, Cox J, Komaki R. PD-088 Image-guided proton radiotherapy for medically inoperable stage I non-small cell lung cancer. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80421-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
157
|
Machtay M, Swann S, Komaki R, Sause W, Langer C, Byhardt R, Curran W. O-042 Overall treatment time during concurrent chemoradiotherapy and outcomes: An RTOG secondary analysis. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80174-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
158
|
Ciangaru G, Tsunashima Y, Sakae T, Smith A, Mohan R, Starkschall G, Dong L, Komaki R, Akine Y, Cox J. SU-FF-T-340: Effect of Marker Implants On Dose Distribution in Proton Therapy. Med Phys 2005. [DOI: 10.1118/1.1998069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
159
|
Choi B, Balter P, Chi P, Zhang L, Dong L, Mohan R, Cox J, Komaki R, Liu H. SU-FF-J-29: Quantification of 4DCT Determined Lung Tumor Motion Based On Image Registration. Med Phys 2005. [DOI: 10.1118/1.1997575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
160
|
Swann RS, Machtay M, Komaki R, Sause WT, Langer CJ, Byhardt RW, Curran WJ. Impact of overall treatment time during concurrent chemoradiotherapy for locally advanced NSCLC: An RTOG secondary analysis. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
161
|
Komaki R, Allen P, Glisson B, Lu C, Fossella F, Liao Z, Jeter M, Stevens C, Chang J, Guerrero T, Blumenschein G. Hyperfractionated/accelerated thoracic radiation therapy (HFXRT) increased survival compared to daily RT (QDRT) for limited small cell lung cancer (LSCLC) with Concurrent Chemotherapy (ChT). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7158] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
162
|
Werner-Wasik M, Swann S, Curran W, Robert F, Komaki R, Lee CP, Jafar S, Share R, Choy H, Blumenschein G. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): An interim overall toxicity report of the RTOG 0324 Trial. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7135] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
163
|
Lu C, Komaki R, Herbst RS, Evans WK, Lee JJ, Truong M, Moore CA, Choy H, Bleyer A, Fisch MJ. A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303): An interim report of toxicity and response. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7144] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
164
|
Sanders K, Guerrero T, Zhang Y, Tapia R, Cody D, Zhang G, Huang T, Komaki R, Price R. TU-EE-A3-06: Sub-Millimeter Three Dimensional Ventilation Imaging of Rodent Lungs. Med Phys 2005. [DOI: 10.1118/1.1998435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
165
|
Liu H, Wang X, Murshed H, Stevens C, Guerrero T, Balter P, Prado K, Liao Z, Chang J, Komaki R, Cox J, Mohan R. TU-E-T-6C-02: Clinical Implementation of IMRT for Lung Cancers. Med Phys 2005. [DOI: 10.1118/1.1999715] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
166
|
Wei X, Liu H, Jang S, Jauregui M, Dong L, Liao Z, Komaki R, Mohan R. SU-FF-T-380: Dose Mass Histogram and Its Application for 4D Treatment Planning. Med Phys 2005. [DOI: 10.1118/1.1998109] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
167
|
Kang Y, Zhang X, Wang H, Chang J, Liao Z, Komaki R, Cox J, Mohan R, Rosen I, Prado K, Balter P, Liu H, Dong L. WE-E-J-6C-06: Proton Treatment Planning for Mobile Lung Tumors. Med Phys 2005. [DOI: 10.1118/1.1998594] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
168
|
Liu H, Wei X, Jang S, Jauregui M, Dong L, Balter P, Luo D, Pan T, Hunjan S, Starkschall G, Rosen I, Prado K, Liao Z, Chang J, Komaki R, Mohan R. SU-FF-J-22: Impact of Respiratory Motion On Dose Distributions and DVHs of Thoracic Structures - Evaluation Using 4DCT. Med Phys 2005. [DOI: 10.1118/1.1997568] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
169
|
Komaki R, Allen P, Glisson B, Milas L, Charles L, Kaplan B, Fossella F, Liao Z, Jeter M, Stevens C, Chang J, Guerrero T. Hyperfractionated and accelerated thoracic radiation therapy (HFXATRT) increased survival compared to daily TRT (QDTRT) for limited small cell lung cancer (LSCLC) patients treated with concurrent chemotherapy. Int J Radiat Oncol Biol Phys 2004. [DOI: 10.1016/j.ijrobp.2004.06.149] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
170
|
Shibuya K, Komaki R, Wu W, Shintani T, Itasaka S, Isobe T, Ryan A, Herbst R, O’Reilly M. Targeted therapy against VEGFR and EGFR signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2004. [DOI: 10.1016/j.ijrobp.2004.06.061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
171
|
Chen Y, Liao Z, Chen Y, Zhang Z, Jing J, Ajani J, Swisher S, Chang J, Guerrero T, Jeter M, Cox J, Komaki R. Treatment outcome of irradiated esophageal cancer. Int J Radiat Oncol Biol Phys 2004. [DOI: 10.1016/j.ijrobp.2004.07.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
172
|
Sanders K, Guerrero T, Zhang G, Bilton S, Stevens C, Lu C, Stewart D, Komaki R. Quantitative measurement of regional tumor response to therapy. Int J Radiat Oncol Biol Phys 2004. [DOI: 10.1016/j.ijrobp.2004.06.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
173
|
Phan AT, Rashid A, Luthra R, Lopez-Alvarez E, Swisher S, Komaki R, Bresalier R, Ajani JA. Molecular predictors of patients with localized upper gastrointestinal cancers after chemoradiation. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
174
|
Komaki R, Spitz MR, Wu X, Chang JY, Allen PK, Lika M, Fossella FV, Stevens CW, Liao Z, Cox JD. Mutagen Sensitivity (MS) may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer (NSCLC) treated by chemoradiotherapy. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
175
|
Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus 2004; 17:38-43. [PMID: 15209739 DOI: 10.1111/j.1442-2050.2004.00355.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Pathologic complete response in the resected esophagus can be achieved in approximately 30% of patients with locally advanced esophageal or gastroesophageal junction carcinoma after preoperative chemoradiation therapy. These patients tend to have a longer survival than those who have less than pathologic complete response. Post-chemoradiation esophageal biopsy (PCEB) is used to check for the presence of residual tumor before a definitive resection is performed, but the clinical significance of PCEB findings is not clear due to the possibility of sampling bias and the superficial nature of the specimen obtained. We evaluated the use of PCEB (defined as biopsy taken within 30 days before esophagectomy) in predicting residual cancer in post-treatment esophagectomy specimens. PCEB was performed in 65 of 183 (36%) patients with locally advanced esophageal or gastroesophageal junction carcinoma, who received preoperative chemoradiation therapy. The cancer status in PCEB was correlated with the residual cancer in the esophagectomy specimens. PCEB had no cancer in 80% (52 of 65) of patients (Bx-negative) and cancer in 20% (13 of 65) of patients (Bx-positive). There was no difference in the presence of residual cancer (either in esophagus or lymph node) in esophagectomy specimens between Bx-negative patients (77%, 40 of 52) or Bx-positive patients (92%, 12 of 13), P = 0.44. The positive predictive value of biopsy was 92% (12 of 13), negative predictive value 23% (12 of 52), sensitivity 23% (12 of 52) and specificity 92% (12 of 13). There was no difference in the residual cancer staging in the esophagectomy specimen between Bx-positive and Bx-negative patients. In contrast, residual metastatic carcinoma in lymph nodes was more frequent in Bx-positive patients (69.2%, 9 of 13) than in Bx-negative patients (28.8%, 15 of 52), P = 0.01. Our data suggest that PCEB is a specific but not a sensitive predictor of residual cancer following esophagectomy. Bx-positive patients tend to have more frequent residual tumor in lymph nodes. The utility of PCEB in predicting residual cancer in the lymph nodes needs to be explored further along with molecular predictors of response to preoperative therapy.
Collapse
|